COPENHAGEN (Reuters) - Danish drugmaker Novo Nordisk, the world's biggest insulin maker, said on Friday that U.S. health regulators had extended their review of its new ultra-long-acting insulin Tresiba, or degludec, to consider further data. The unexpected delay is a disappointment since degludec is a pivotal new product with which Novo hopes to consolidate its position in the fast-growing diabetes market. Shares in the group fell 3.1 percent by 0740 GMT. ...
Read more
No comments:
Post a Comment